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Abstract : A 79-year-old woman presented to our hospital with frequent episodes 
of hematochezia.  Colonoscopy revealed an apparent tumor with central ulcer-
ation, and analysis of biopsy specimens confirmed the presence of non-invasive 
squamous cell carcinoma of the anal canal.  No distant metastases were identied 
on enhanced computed tomography （CT）.  The cancer was classied as stage II 
（T2N0M0）, and chemoradiotherapy （CRT） was selected as the rst-line treatment.  
A continuous intravenous infusion of 5-uorouracil with daily cisplatin was planned 
on days 1 to 5 of a 4-week cycle.  After the rst course, the drug administration 
was discontinued because the patient experienced diarrhea as an adverse event, and 
treatment with daily oral titanium silicate-1 （TS-1） was initiated.  In addition, a 
total of 65 Gy of radiation was applied to the primary lesion, pelvis, and bilateral 
groin area.  Four weeks after the completion of CRT, colonoscopy showed the dis-
appearance of the tumor and analysis of biopsy specimens conrmed the absence 
of any viable cancer cells.  CT showed no evidence of lymph node metastasis or 
distant metastases.  At 10 months after the completion of CRT, the patient showed 
no recurrence and with complete response.
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Introduction
　Although squamous cell carcinoma of the anal canal （SCCA） is an uncommon malignancy, 
its incidence is currently increasing 1, 2）.  Historically, anal cancer was managed surgically with 
abdominoperineal resection （APR）, but since the landmark publication by Nigro et al, 1974, 
chemoradiotherapy （CRT） has been the mainstay of treatment 3）.  CRT has superseded surgery 
because it affords equivalent survival with the benefit of a better functional outcome, because a 
colostomy is not required.  We report a case of SCCA in which a complete response （CR） was 
achieved with CRT using titanium silvcare-1 （TS-1）.
Case Report
　A 79-year-old woman presented to our hospital with frequent episodes of hematochezia.  The 
patient had no significant medical history of inflammatory bowel disease, did not drink alcohol, 
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and was a non-smoker.  Digital rectal examination revealed an anal canal tumor in the anterior 
wall ; the bilateral inguinal lymph nodes were not swollen.  At presentation, the patient had a 
body temperature of 36.6℃, blood pressure of 120 / 75 mmHg, a pulse rate of 70 beats / min, 
and a respiratory rate of 17 breaths / min.  She was in good general condition, with normal 
vital signs.  On physical examination, the abdomen was relatively soft.  The white blood cell 
count was 11,100 cells /μl.  Serum electrolyte levels were within normal ranges.  The levels of 
carcinoembryonic antigen （CEA） and squamous cell carcinoma antigen（SCC-Ag） were within 
normal limits （Table 1）.
　Colonoscopy showed an apparent tumor with central ulceration located in the anterior wall of 
the anal canal and lower rectum （Fig. 1）.  Analysis of biopsy specimens confirmed the presence 
of non-invasive SCCA.  CT showed no evidence of lymph node or distant metastases （Fig. 2）. 
The cancer was classified as stage II （T2N0M0）, and CRT was selected as the first-line therapy.
　After we obtained informed consent from the patient, continuous intravenous infusion of 
5-fluorouracil （5-FU） （710 mg / day） with daily cisplatin （CDDP） （10 mg / day） was planned on 
days 1 to 5 of a 4-week cycle.  However, administration was discontinued after the first course 
because the patient experienced diarrhea, and the chemotherapy regimen was changed to daily 
oral TS-1.  Each course consisted of daily oral TS-1 （80 mg） for 4 weeks followed by 2 drug-
free weeks.  In addition, a total of 65 Gy of radiation was applied to the primary lesion, pelvis, 
and bilateral groin area.  Drug-induced diarrhea （grade 2） developed after completion of the 
Fig. 1.  Colonoscopy
Colonoscopy showing an apparent tumor （arrows） 
with central ulceration located in the anterior wall 
of the anal canal and lower rectum.
Table 1.  Tumor marker of CEA and SCC
Before CRT After CRT
CEA （ng / ml） 1.1 0.9
SCC （ng / ml） 0.8 0.6
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second cycle, and the TS-1 dose was reduced to 40 mg / body to allow improvement.  Three 
cycles of chemotherapy were performed in total （total dose of TS-1, 4,480 mg as tegafur）.
　Four weeks after CRT completion, colonoscopy showed the disappearance of the tumor （Fig. 
3） and analysis of biopsy specimens confirmed the absence of any viable cancer cells.  CT 
showed no evidence of lymph node or distant metastases, as was the case on the initial CT 
（Fig. 4）.  At 10 months after CRT completion, the patient showed no recurrence with complete 
Fig. 3.  Colonoscopy at 4 weeks after the completion of chemoradiotherapy
Colonoscopy showing the disappearance of the tumor （A, arrows）. Narrow band 
imaging showing only cicatricial tissue （B, arrows）.
Fig. 4.  Computed tomography at 4 weeks after the completion of chemoradiotherapy
CT showing no evidence of lymph node or distant metastases, as was the case on the 
initial computed tomography.
Fig. 2.  Computed tomography
CT showing no evidence of lymph node or distant metastases.
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response （CR）.  Colonoscopy and narrow band imaging showed no recurrence of SCCA （Fig. 
5）.  The patient continues to undergo outpatient treatment.
Discussion
　SCCA is a relatively rare tumor, representing 2～ 4％ of all cancers of the colorectum and 
anus 4）, but its incidence is increasing 1, 2）.  Up to 45％ of patients with SCCA present with rectal 
bleeding.  Other symptoms include rectal pain and / or a mass sensation, which occur in 30％ of 
patients.  The presentation of an anal canal tumor is often nonspecific, and 70～ 80％ of patients 
are initially diagnosed with a benign anorectal condition such as hemorrhoids.  We recommend 
that a thorough clinical history and physical examination with careful rectal examination is 
mandatory for all patients with suspected anal canal cancer.  Approximately 20％ of patients 
have no symptoms at the time of diagnosis 5, 6）.  Colonoscopy is required to rule out synchronous 
colorectal neoplasms 7）.  In the case described here, the patient had frequent episodes of 
hematochezia and colonoscopy revealed an apparent tumor of the anal canal.
　Endoscopic mucosal biopsy is a standard tool for histological diagnosis.  The chemotherapy 
regimen comprising 5-FU and mitomycin-C is the most commonly used among patients with 
anal carcinoma but it causes well-documented toxicities.  Hung et al 8） reported that combined 
modality therapy with continuous infusion of CDDP and 5-FU was a well-tolerated regimen that 
results in high rates of local control, overall survival, and sphincter preservation.  And these rates 
were comparable to the best results reported with mitomycin-C and 5-FU 8, 9） （Table 2）.  In 
Table 2.  Impact of radiation therapy plus 5-FU / MMC vs radiation therapy plus 5-FU / CDDP
n chemotherapy
5-year overall survival
（％）
disease-free survival
（％）
Hung A et al 8） 92 5-FU / CDDP 85 77
Bartelink et al 9） 51 5-FU / MMC 56 58
Fig. 5.  Colonoscopy at 10 months after completion of chemoradiotherapy
Colonoscopy and narrow band imaging showing no recurrence of squamous cell 
carcinoma of the anal canal （A, B, arrows）.
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Japan, a Phase I / II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients 
with clinical Stage II / III squamous cell carcinoma of the anal canal （JCOG0903 : SMART-AC） 
was undertaken 10）.  After we obtained informed consent from the patient, continuous intravenous 
infusion of 5-FU and CDDP was started.  After the first course of 5-FU and CDDP, the patient 
experienced diarrhea as an adverse event.  The chemotherapy regimen had to be changed to 
daily oral TS-1 from 5-FU.  TS-1 is an oral anticancer drug, which was developed based on 
the biochemical modulation of tegafur by gimeracil and oteracil.  The antitumor effect of TS-1 
has already been demonstrated in patients with a variety of solid tumors, including advanced 
gastric cancer 11）, colorectal cancer 12）, non-small cell lung cancer 13）, and head and neck cancer 14）. 
Because drug-induced diarrhea （grade 2） developed after completion of the second cycle, the 
TS-1 dose was reduced to 40 mg / body to allow improvement after an off-period of one month. 
Three cycles of chemotherapy were administered in total.
　We report a case of SCCA in which a complete response was achieved with CRT using 
TS-1 allowing preservation of the anal sphincter and avoidance of a permanent colostomy. 
APR is now reserved as a salvage therapy for those individuals with persistent disease after 
combined CRT.  At 10 months after CRT completion, the patient has had no recurrence and 
no complications.  The findings of this case suggest that CRT with TS-1 may be effective for 
treating SCCA.
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